EUVIMEDEUVIMED entdecken
Crossref

RCN2 facilitates esophageal squamous cellular carcinoma metastasis and cisplatin resistance through UBR5-mediated PPP2CA ubiquitination and degradation

Mengyuan Wu, Xu Huang, Miao Lin, Zhiyun Duan, Zitao Jian, Runze You, Peiyi Xie, Zhiwei Wu, Siyun Lin, Shaoyuan Zhang, Wenyi Xu, Heng Jiao und 5 weitere

Drug Resistance Updates · 2026

DOI: 10.1016/j.drup.2025.101339 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2026. Verfasst von Mengyuan Wu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China. Hauptthemen laut MEDLINE: Cisplatin, Drug Resistance, Neoplasm, Esophageal Squamous Cell Carcinoma, Protein Phosphatase 2. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 71 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Fujian Provincial Health Technology Project, Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: Metastatic progression and treatment resistance determine poor prognostic outcomes of patients with esophageal squamous cellular carcinoma (ESCC), highlighting the urgent need to understand the molecular mechanisms behind this. Reticulocalbin 2 (RCN2) is a calcium-binding protein localized in the endoplasmic reticulum lumen, which mediates tumor progression in various cancer types. However, the role of RCN2 in ESCC remains unexplored. METHODS: The influence of RCN2 on ESCC progression, metastasis, and cisplatin (CDDP) resistance was assessed both in vitro and in vivo. The downstream regulatory mechanism associated with RCN2 was screened through RNA-seq, TMT 10X mass spectrometry analysis, and LC-MS/MS analysis, which was further validated through Western blot, immunoprecipitation, immunofluorescence, GST pull-down assay, and rescue experiments. RESULTS: We observed high RCN2 expression in ESCC tumor tissues from patients with metastasis, which is correlated with a higher risk of metastasis and worse survival. PPP2CA, a catalytic subunit of protein phosphatase 2 A (PP2A), and ubiquitin protein ligase E3 component N-recognin 5 (UBR5) are determined as novel RCN2 functioning interactors. Mechanistically, RCN2 facilitates PPP2CA ubiquitination and degradation dependent on the HECT domain of UBR5, thereby activating the PI3K-AKT signaling pathway. Furthermore, the activated RCN2-PPP2CA-PI3K-AKT axis is validated in clinical specimens of ESCC. Finally, targeted suppression of RCN2 synergized with CDDP treatment to prevent tumor growth and metastasis in subcutaneous and lung metastasis models. CONCLUSIONS: Overall, these findings identify RCN2 as a novel driver of ESCC metastasis and CDDP resistance. RCN2 could be a promising treatment target for ESCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinDrug Resistance, NeoplasmEsophageal Squamous Cell CarcinomaProtein Phosphatase 2Esophageal NeoplasmsUbiquitin-Protein LigasesCalcium-Binding ProteinsHumansUbiquitinationAnimalsMiceCell Line, TumorAntineoplastic AgentsNeoplasm MetastasisMice, NudeSignal TransductionXenograft Model Antitumor AssaysMice, Inbred BALB CFemaleGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

Cisplatin resistanceEsophageal squamous cell carcinomaMetastasisPI3K-AKT signaling pathwayRCN2

Substanzen

CisplatinProtein Phosphatase 2Ubiquitin-Protein LigasesUBR5 protein, humanPPP2CA protein, humanAntineoplastic AgentsCalcium-Binding Proteins

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
  • Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai 200032, China.
  • Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China. Electronic address: wang.hao@zs-hospital.sh.cn.
  • Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China. Electronic address: guo.weigang@zs-hospital.sh.cn.
  • Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China. Electronic address: tan.lijie@zs-hospital.sh.cn.

Förderung

  • National Natural Science Foundation of China
  • Fujian Provincial Health Technology Project
  • Science and Technology Commission of Shanghai Municipality

Zitieren

APA

Wu, M., Huang, X., Lin, M., Duan, Z., Jian, Z., You, R., Xie, P., Wu, Z., Lin, S., Zhang, S., Xu, W., Jiao, H., Tang, H., Guo, L., Wang, H., Guo, W., & Tan, L. (2026). RCN2 facilitates esophageal squamous cellular carcinoma metastasis and cisplatin resistance through UBR5-mediated PPP2CA ubiquitination and degradation. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2025.101339

Vancouver

Wu M, Huang X, Lin M, Duan Z, Jian Z, You R, et al. RCN2 facilitates esophageal squamous cellular carcinoma metastasis and cisplatin resistance through UBR5-mediated PPP2CA ubiquitination and degradation. Drug Resistance Updates. 2026. doi:10.1016/j.drup.2025.101339

BibTeX
@article{Wu2026,
  author = {Wu, Mengyuan and Huang, Xu and Lin, Miao and Duan, Zhiyun and Jian, Zitao and You, Runze and Xie, Peiyi and Wu, Zhiwei and Lin, Siyun and Zhang, Shaoyuan and Xu, Wenyi and Jiao, Heng and Tang, Han and Guo, Lei and Wang, Hao and Guo, Weigang and Tan, Lijie},
  title = {RCN2 facilitates esophageal squamous cellular carcinoma metastasis and cisplatin resistance through UBR5-mediated PPP2CA ubiquitination and degradation},
  journal = {Drug Resistance Updates},
  year = {2026},
  doi = {10.1016/j.drup.2025.101339}
}
Kostenlos starten →